CARMAT (Velizy Villacoublay, France) today announced that its bioprosthetic total artificial heart is now scheduled to be trialed for the first time in human patients at four medical centers in Europe and Middle East. The CARMAT heart is intended to be used as an end-stage device, completely replacing the patient’s own and hopefully avoiding the many complications of transplantation.
The artificial heart consists of two cavities, mimicking the organ’s ventricles, which are separated by a moving membrane that’s hydraulically powered via a special actioning fluid. This membrane reproduces the action of the ventricular wall during contractions, creating blood flow in and out of the device. The system is works in conjunctions with sensors and a microcontroller that continuously adjust the activity of the prosthesis to match the needs of the patient.
Here’s a video presenting the CARMAT bioprosthetic heart:
Product page: CARMAT heart…